Table of Contents Author Guidelines Submit a Manuscript
International Journal of Genomics
Volume 2017 (2017), Article ID 2913648, 13 pages
https://doi.org/10.1155/2017/2913648
Research Article

Differential Analysis of Genetic, Epigenetic, and Cytogenetic Abnormalities in AML

1Pharmacogenomics Lab, Department of Pharmacology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
2Computational Epigenomics Group, Division of Epigenomics and Cancer Risk Factor, German Cancer Research Center, Heidelberg, Germany
3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Correspondence should be addressed to Zahurin Mohamed; ym.ude.mu@niruhaz and Yassen Assenov; ed.zfkd@vonessa.y

Received 14 November 2016; Revised 21 March 2017; Accepted 18 April 2017; Published 20 June 2017

Academic Editor: Brian Wigdahl

Copyright © 2017 Mirazul Islam et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. G. Tenen, “Disruption of differentiation in human cancer: AML shows the way,” Nature Reviews Cancer, vol. 3, no. 2, pp. 89–101, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Mehdipour, F. Santoro, and S. Minucci, “Epigenetic alterations in acute myeloid leukemias,” FEBS Journal, vol. 282, no. 9, pp. 1786–1800, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Siegel, J. Ma, Z. Zou, and A. Jemal, “Cancer statistics, 2014,” CA: A Cancer Journal for Clinicians, vol. 64, no. 1, pp. 9–29, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. J. C. Byrd, K. Mrózek, R. K. Dodge et al., “Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461),” Blood, vol. 100, no. 13, pp. 4325–4336, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Christopeit and B. Bartholdy, “Epigenetic signatures as prognostic tools in acute myeloid leukemia and myelodysplastic syndromes,” Epigenomics, vol. 6, no. 4, pp. 371–374, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. J. W. Vardiman, J. Thiele, D. A. Arber et al., “The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes,” Blood, vol. 114, no. 5, pp. 937–951, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. J. P. Patel, M. Gönen, M. E. Figueroa et al., “Prognostic relevance of integrated genetic profiling in acute myeloid leukemia,” New England Journal of Medicine, vol. 366, no. 12, pp. 1079–1089, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Shen, Y. M. Zhu, X. Fan et al., “Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia,” Blood, vol. 118, no. 20, pp. 5593–5603, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Bock, I. Beerman, W. H. Lien et al., “DNA methylation dynamics during in vivo differentiation of blood and skin stem cells,” Molecular Cell, vol. 47, no. 4, pp. 633–647, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Ji, L. I. Ehrlich, J. Seita et al., “Comprehensive methylome map of lineage commitment from haematopoietic progenitors,” Nature, vol. 467, no. 7313, pp. 338–342, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. Network CGAR, “Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia,” The New England Journal of Medicine, vol. 368, no. 22, p. 2059, 2013. View at Publisher · View at Google Scholar
  12. I. Lokody, “Epigenetics: histone methyltransferase mutations promote leukaemia,” Nature Reviews Cancer, vol. 14, no. 4, pp. 214-215, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Qu, A. Lennartsson, V. I. Gaidzik et al., “Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by DNMT3A mutational status and associated with predominant hypomethylation of HOX genes,” Epigenetics, vol. 9, no. 8, pp. 1108–1119, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Delhommeau, S. Dupont, V. Della Valle et al., “Mutation in TET2 in myeloid cancers,” New England Journal of Medicine, vol. 360, no. 22, pp. 2289–2301, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Michaux, I. Wlodarska, M. Stul et al., “MLL amplification in myeloid leukemias: a study of 14 cases with multiple copies of 11q23,” Genes, Chromosomes and Cancer, vol. 29, no. 1, pp. 40–47, 2000. View at Publisher · View at Google Scholar
  16. M. E. Figueroa, O. Abdel-Wahab, C. Lu et al., “Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation,” Cancer Cell, vol. 18, no. 6, pp. 553–567, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. J. H. Mendler, K. Maharry, M. D. Radmacher et al., “RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures,” Journal of Clinical Oncology, vol. 30, no. 25, pp. 3109–3118, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. W. C. Chou, H. H. Huang, H. A. Hou et al., “Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations,” Blood, vol. 116, no. 20, pp. 4086–4094, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Eppert, K. Takenaka, E. R. Lechman et al., “Stem cell gene expression programs influence clinical outcome in human leukemia,” Nature Medicine, vol. 17, no. 9, pp. 1086–1093, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Schoch, A. Kohlmann, S. Schnittger et al., “Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles,” Proceedings of the National Academy of Sciences, vol. 99, no. 15, pp. 10008–10013, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. A. J. Gentles, S. K. Plevritis, R. Majeti, and A. A. Alizadeh, “Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia,” Jama, vol. 304, no. 24, pp. 2706–2715, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Christopeit, N. Kröger, T. Haferlach, and U. Bacher, “Relapse assessment following allogeneic SCT in patients with MDS and AML,” Annals of Hematology, vol. 93, no. 7, pp. 1097–1110, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. J. M. Bennett, D. Catovsky, M. T. Daniel et al., “Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group,” British Journal of Haematology, vol. 33, no. 4, pp. 451–458, 1976. View at Publisher · View at Google Scholar
  24. J. W. Vardiman, N. L. Harris, and R. D. Brunning, “The World Health Organization (WHO) classification of the myeloid neoplasms,” Blood, vol. 100, no. 7, pp. 2292–2302, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. J. N. Weinstein, Cancer Genome Atlas Research Network, E. A. Collisson et al., “The cancer genome atlas pan-cancer analysis project,” Nature Genetics, vol. 45, no. 10, pp. 1113–1120, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Assenov, F. Müller, P. Lutsik, J. Walter, T. Lengauer, and C. Bock, “Comprehensive analysis of DNA methylation data with RnBeads,” Nature Methods, vol. 11, no. 11, pp. 1138–1140, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Bock, “Analysing and interpreting DNA methylation data,” Nature Reviews Genetics, vol. 13, no. 10, pp. 705–719, 2012. View at Publisher · View at Google Scholar
  28. C. Bock, J. Walter, M. Paulsen, and T. Lengauer, “Inter-individual variation of DNA methylation and its implications for large-scale epigenome mapping,” Nucleic Acids Research, vol. 36, no. 10, pp. e55–e55, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. D. Grimwade, R. K. Hills, A. V. Moorman et al., “Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials,” Blood, vol. 116, no. 3, pp. 354–365, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Hehlmann, D. Grimwade, B. Simonsson et al., “The European LeukemiaNet-Achievements and perspectives,” Haematologica, vol. 96, no. 1, pp. 156–162, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Marcucci, T. Haferlach, and H. Döhner, “Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications,” Journal of Clinical Oncology, vol. 29, no. 13, p. 1798, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. I. Lahortiga and J. Cools, “New Opportunities and New Problems for Acute Myeloid Leukemia Treatment,” Haematologica, vol. 97, p. 796, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. M. E. Figueroa, S. Lugthart, Y. Li et al., “DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia,” Cancer Cell, vol. 17, no. 1, pp. 13–27, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Deneberg, M. Grövdal, M. Karimi et al., “Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia,” Leukemia, vol. 24, no. 5, pp. 932–941, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Yalcin, C. Kreutz, D. Pfeifer et al., “MeDIP coupled with a promoter tiling array as a platform to investigate global DNA methylation patterns in AML cells,” Leukemia Research, vol. 37, no. 1, pp. 102–111, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. M. M. Suzuki and A. Bird, “DNA methylation landscapes: provocative insights from epigenomics,” Nature Reviews Genetics, vol. 9, no. 6, pp. 465–476, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. S. De, R. Shaknovich, M. Riester et al., “Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity,” PLoS Genetics, vol. 9, no. 1, article e1003137, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Suzuki, M. Oda, M. P. Ramos et al., “Late-replicating heterochromatin is characterized by decreased cytosine methylation in the human genome,” Genome Research, vol. 21, no. 11, pp. 1833–1840, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. N. Cahill, A. C. Bergh, M. Kanduri et al., “450K-array analysis of chronic lymphocytic leukemia cells reveals global DNA methylation to be relatively stable over time and similar in resting and proliferative compartments,” Leukemia, vol. 27, no. 1, pp. 150–158, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. R. A. Irizarry, C. Ladd-Acosta, B. Wen et al., “The human colon cancer methylome shows similar hypo-and hypermethylation at conserved tissue-specific CpG island shores,” Nature Genetics, vol. 41, no. 2, pp. 178–186, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Akalin, F. E. Garrett-Bakelman, M. Kormaksson et al., “Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia,” PLoS Genetics, vol. 8, no. 6, article e1002781, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. L. M. Butcher, M. Ito, M. Brimpari et al., “Non-CG DNA methylation is a biomarker for assessing endodermal differentiation capacity in pluripotent stem cells,” Nature Communications, vol. 7, article 10458, 2016. View at Publisher · View at Google Scholar · View at Scopus
  43. C. Holz-Schietinger, D. M. Matje, and N. O. Reich, “Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation,” Journal of Biological Chemistry, vol. 287, no. 37, pp. 30941–30951, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. Y. Y. Zhang, D. M. Yao, X. W. Zhu et al., “DNMT3A intragenic hypomethylation is associated with adverse prognosis in acute myeloid leukemia,” Leukemia Research, vol. 39, no. 10, pp. 1041–1047, 2015. View at Publisher · View at Google Scholar · View at Scopus
  45. E. Jost, Q. Lin, C. I. Weidner et al., “Epimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia,” Leukemia, vol. 28, no. 6, pp. 1227–1234, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. M. M. Islam, Z. Mohamed, and Y. Assenov, “Differential analysis of genetic, epigenetic, and cytogenetic abnormalities in AML,” in Poster session (P-PG-04) presented at the 13th Asia Pacific Federation of Pharmacologist (APFP) Meeting, Bangkok, Thailand, February 2016. View at Publisher · View at Google Scholar